Since December 1, 2020, Taiwan's National Health Insurance (NHI) has covered Vagus Nerve Stimulation Therapy System to support patients with epilepsy. Building on this commitment, the LivaNova Vagus Nerve Stimulation Therapy System, an advanced treatment option, was officially added to the NHI program on February 1, 2025. This cutting-edge device is expected to significantly improve seizure management, enhancing the quality of life for individuals with epilepsy.
The introduction of the LivaNova Vagus Nerve Stimulation Therapy System represents a major advancement in epilepsy care. Key benefits of this innovative therapy include:
- Real-Time Seizure Prevention: The device automatically detects heart rate changes and delivers timely pulses to help prevent seizures.
- Fewer Hospital Visits: Advanced programming features reduce the need for frequent adjustments, offering greater convenience and flexibility for patients.
- Enhanced Safety and Efficacy: Improved design features ensure greater stability and effectiveness, enabling patients to lead more predictable and higher-quality lives.
With its inclusion in the NHI program, the LivaNova Vagus Nerve Stimulation Therapy System is expected to benefit approximately 113 patients annually. The NHIA has allocated 5.52 million points to this initiative, expanding access to state-of-the-art epilepsy treatment. Committed to integrating health technology advancements, the NHIA continues to enhance patient care and safeguard the health of all individuals.